MoonLake Immunotherapeutics
Last updated September 27, 2026
Organization details
- Legal name
- MoonLake Immunotherapeutics
- Former names
- Helix Acquisition Corp
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Cayman Islands
- Headquarters city
- ZUG
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- MLTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001821586
Board of directors
-
Andrew John Phillips · DirectorSince 2023
-
Catherine Moukheibir · DirectorSince 2023
-
Da Silva Jorge Santos · Director · Chief Executive OfficerSince 2023
-
Mark N. Lampert · DirectorSince 2023
-
Ramnik Xavier · DirectorSince 2023
-
Simon Sturge · DirectorSince 2023
-
Spike Loy · DirectorSince 2023
Chief executives
Da Silva Jorge Santos
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of June 4, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
92.4%
Board connections
3 of this board's directors also sit on 6 other boards.
- via Andrew John Phillips
- via Mark N. Lampert
- via Catherine Moukheibir
- via Mark N. Lampert
- via Mark N. Lampert
- via Andrew John Phillips
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $98,808
- 1 purchase by 1 insider
- Sold, last 12 months
- $129,894,803
- 32 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 27, 2026 | Reich Kristian Officer (Chief Scientific Officer) | Open-market sale | −1,100 | $20.00 | $22,000 |
| Jul 22, 2026 | Reich Kristian Officer (Chief Scientific Officer) | Open-market sale | −2,448 | $20.00 | $48,960 |
| Jul 21, 2026 | Reich Kristian Officer (Chief Scientific Officer) | Open-market sale | −50,000 | $20.02 | $1,001,000 |
| Jul 20, 2026 | Reich Kristian Officer (Chief Scientific Officer) | Open-market sale | −43,700 | $20.09 | $877,933 |
| Jul 15, 2026 | Reich Kristian Officer (Chief Scientific Officer) | Open-market sale | −16,105 | $20.01 | $322,261 |
| Jul 10, 2026 | Da Silva Jorge Santos Director, Officer (Chief Executive Officer) | Open-market sale | −68,289 | $20.02 | $1,367,146 |
| Jul 9, 2026 | Da Silva Jorge Santos Director, Officer (Chief Executive Officer) | Open-market sale | −33,936 | $20.01 | $679,059 |
| Jul 1, 2026 | Da Silva Jorge Santos Director, Officer (Chief Executive Officer) | Open-market sale | −47,775 | $20.03 | $956,933 |
| Jun 22, 2026 | Bodenstedt Matthias Officer (Chief Financial Officer) | Open-market sale | −39,120 | $22.04 | $862,205 |
| Jun 18, 2026 | Bodenstedt Matthias Officer (Chief Financial Officer) | Open-market sale | −2,794 | $19.60 | $54,762 |
| Jun 17, 2026 | Bodenstedt Matthias Officer (Chief Financial Officer) | Open-market sale | −15,082 | $19.68 | $296,814 |
| Jun 17, 2026 | Reich Kristian Officer (Chief Scientific Officer) | Open-market sale | −50,000 | $19.43 | $971,500 |
| Jun 16, 2026 | Reich Kristian Officer (Chief Scientific Officer) | Open-market sale | −50,000 | $18.70 | $935,000 |
| Jun 15, 2026 | Reich Kristian Officer (Chief Scientific Officer) | Open-market sale | −50,000 | $18.89 | $944,500 |
| May 11, 2026 | Bodenstedt Matthias Officer (Chief Financial Officer) | Open-market sale | −13,653 | $20.02 | $273,333 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.